France Ypsomed Websites
  • Switzerland (Group)
  • Australia
  • Austria
  • Belgium
  • Canada
  • 中文
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Poland
  • Spain
  • Sweden
  • United Kingdom
Ypsomed Group
Aller au contenu
  • About Ypsomed Group
  • Jobs & Careers
  • Media & Investors
 
Ypsomed Logo
Aller au contenu
  • Entreprise
  • Produits & Services
  • Dernières nouvelles
  • Contact
 

Communiqués

Administration d’un bolus depuis un smartphone vers la pompe à insuline mylife YpsoPump

30/08/2022 - 07:00 Notizie Ypsomed Italia

Berthoud - Ypsomed lance l'administration de bolus depuis un smartphone vers la pompe à insuline mylife YpsoPump1 via l'application mylife App. Cette nouvelle fonctionnalité permet aux utilisateurs de mylife YpsoPump d'administrer un bolus d'insuline de manière pratique et discrète via un smartphone, sans avoir à manipuler directement la pompe. Suite au lancement au début de l'été, dans certains pays Européens, de l'administration automatisée d'insuline (AAI) via l'application mylife CamAPS FX, Ypsomed propose désormais une option supplémentaire d'administration discrète de bolus à distance aux personnes diabétiques, leur permettant de choisir une solution thérapeutique répondant à leurs besoins.

En savoir plus... Administration d’un bolus depuis un smartphone vers la pompe à insuline mylife YpsoPump

Ypsomed, Abbott and CamDiab unveil new automated insulin delivery partnership for people with diabetes

27/04/2022 - 06:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed, Abbott and CamDiab will work to accelerate the development of an automated insulin delivery system for people living with diabetes. The system is being designed to include Abbott’s FreeStyle Libre 3 sensor, CamDiab’s CamAPS FX algorithm, and Ypsomed’s mylife YpsoPump. The partnership demonstrates the companies’ collective desire to drive integrated solutions to help people with diabetes better manage their condition and improve health outcomes.

En savoir plus... Ypsomed, Abbott and CamDiab unveil new automated insulin delivery partnership for people with diabetes

Ypsomed continues to invest in growth

Ypsomed continues to invest in growth

26/05/2021 - 07:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed (SWX: YPSN) increased its consolidated sales by CHF 9.4 million to CHF 403.7 million in the financial year 2020/21 (prior year: CHF 394.3 million). The two business segments developed differently during the Corona pandemic: while the business with pens and autoinjectors was encouraging, the sales of insulin pumps remained at a low level. Ypsomed has set an important course in the financial year 2020/21 to improve the sales opportunities for YpsoPump. The increased importance of self-treatment of chronic diseases has reinforced the company’s growth strategy. Ypsomed has therefore advanced all strategic initiatives and further improved its own competitive position. The company invested a total of CHF 142.7 million for this purpose while at the same time creating 110 new jobs. To expand financial flexibility for the future, the Board of Directors will propose an authorised increase in capital at the Annual General Meeting.

En savoir plus... Ypsomed continues to invest in growth

World's first zero carbon emission autoinjector from Ypsomed

World's first zero carbon emission autoinjector from Ypsomed

02/10/2020 - 07:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed has developed the world’s first zero carbon emission prefilled autoinjector. The YpsoMate Zero is based on the proven YpsoMate autoinjector platform that offers convenient handling and patient safety. The new YpsoMate Zero uses alternative biopolymers and a novel packaging design that follows the principles of circular product design.

En savoir plus... World's first zero carbon emission autoinjector from Ypsomed

Ypsomed’s Annual General Meeting approves all proposals and elects Gilbert Achermann as a new member of the Board of Directors

Ypsomed’s Annual General Meeting approves all proposals and elects Gilbert Achermann as a new member of the Board of Directors

02/07/2020 - 07:00 Press Releases Ypsomed Group

Burgdorf – Yesterday, the Annual General Meeting of the Ypsomed Group has approved all proposals and has elected Gilbert Achermann as a new member of the Board of Directors and of the Compensation Committee to succeed Anton Kräuliger. Gilbert Achermann is Chairman of the Board of Directors of the Straumann Group as well as member of the Board of Directors of Vifor Pharma Ltd and Julius Baer Group Ltd.

En savoir plus... Ypsomed’s Annual General Meeting approves all proposals and elects Gilbert Achermann as a new member of the Board of Directors

  • 1
  • 2
  • 3
  • 4
Thomas Kutt
Head of Investor Relations
Ypsomed Holding AG
Brunnmattstrasse 6
3401 Burgdorf
Suisse
thomas.kutt@ypsomed.com
+41 34 424 35 55
TOP
Aller au contenu
  • Mentions légales
  • Conditions générales
  • Protection des données
  • À propos des cookies
  • Déclaration de transparence
 
Aller au contenu
  • Plan du site
 

Contact

Ypsomed S.A.S.
44 rue Lafayette
75009 Paris
France

F +33 158 702001
Numéro vert: 0800 883058
info@ypsomed.fr

Dernière mise à jour de la page: 10/10/2022 - 17:13 ©
Ypsomed Logo

Vous êtes sur le point de quitter le site de Ypsomed France

Vous avez cliqué sur un lien conduisant à un autre site Web. Si vous poursuivez, vous pourrez visiter un site géré par un tiers.

Nous n’examinons ni ne contrôlons le contenu des autres sites internet et déclinons toute responsabilité quant aux accords ou transactions commerciales que vous pourriez y conclure. Votre navigation sur cet autre site est soumise à ses propres conditions générales et accords de confidentialité.

Il est possible que certains produits de cet autre site ne soient pas homologués dans votre région ou votre pays.

Annuler Continuer